GLP-1 receptor agonists, such as liraglutide, semaglutide, and exenatide, have been shown to decrease systemic inflammation by reducing circulating levels of inflammatory biomarkers, including hsCRP, TNF-α, and IL-6, in people with type 2 diabetes, obesity, and cardiovascular disease. The gene discussed is TNF; the disease is type 2 diabetes mellitus.